Therapix Biosciences Ltd.
TRPX
TRPX was delisted on the 1st of July, 2020.
6 hedge funds and large institutions have $93K invested in Therapix Biosciences Ltd. in 2018 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
21% more capital invested
Capital invested by funds: $77K → $93K (+$16K)
20% more funds holding
Funds holding: 5 → 6 (+1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$16.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$5.77K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $52K | -$5.77K | -1,000 | -10% |
|
2
Acadian Asset Management
Boston,
Massachusetts
| $23K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $17K | +$16.7K | +2,900 | New |
|
|
PA
4
Parallel Advisors
San Francisco,
California
| $1K | – | – | – |
|
TRPX Hedge Fund Activity: Q1 2018 in Review
6 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Therapix Biosciences Ltd. (TRPX) for Q1 2018, worth a combined $93K — up 21% from $77K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new TRPX positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $16.7K. The largest seller was Morgan Stanley, cutting an estimated $5.77K.
- 6 institutional investors held Therapix Biosciences Ltd. (TRPX) as of Q1 2018, up from 5 in Q4 2017.
- Funds reported $93K of Therapix Biosciences Ltd. stock for Q1 2018, up 21% quarter-over-quarter.
- 1 fund opened new Therapix Biosciences Ltd. positions in Q1 2018 and 0 closed out, a net change of +1 holder.
- The largest Therapix Biosciences Ltd. buyer in Q1 2018 was UBS Group, an estimated $16.7K added.
- The largest Therapix Biosciences Ltd. seller in Q1 2018 was Morgan Stanley, an estimated $5.77K sold.
Based on aggregated 13F filings for Q1 2018.